Kiniksa Pharmaceuticals International, plc

As of June 30, 2026, Kiniksa Pharmaceuticals International, plc carries a market capitalization of 4.99B, placing it among publicly traded companies globally. Its enterprise value stands at 4.47B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Kiniksa Pharmaceuticals International, plc's next confirmed earnings release is scheduled for November 3, 2026.

As of June 30, 2026, Kiniksa Pharmaceuticals International, plc has 77.98M shares outstanding.

As of June 30, 2026, Kiniksa Pharmaceuticals International, plc trades at a trailing price-to-earnings ratio of 60.41. The price-to-sales ratio is 5.79, and the price-to-book ratio stands at 7.62.

As of June 30, 2026, Kiniksa Pharmaceuticals International, plc trades at an EV/EBITDA multiple of 43.80 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 5.32 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 44.59 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Kiniksa Pharmaceuticals International, plc trades at an EV/FCF ratio of 24.45, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 4.47B versus a market cap of 4.99B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Kiniksa Pharmaceuticals International, plc maintains a current ratio of 3.90, meaning it holds 3.9x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Kiniksa Pharmaceuticals International, plc posted a return on equity (ROE) of 14.04, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 12.12 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 10.36, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 13.81, useful for judging operating efficiency across full business cycles. The company generates approximately 2.38M in revenue per employee across its workforce of 353.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 6.42 indicates how many times Kiniksa Pharmaceuticals International, plc sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Kiniksa Pharmaceuticals International, plc recorded 33.59M in income tax expense. That works out to an effective tax rate of 29.40, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 114.25M, leaving 80.66M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Kiniksa Pharmaceuticals International, plc's stock has gained approximately 107.69% over the past 52 weeks. The 50-day moving average sits at 78.13, while the 200-day moving average is 58.82.

Over the twelve months ended June 30, 2026, Kiniksa Pharmaceuticals International, plc generated 840.85M in revenue and converted that into 80.66M in net income, yielding earnings per share of 0.99. EBITDA reached 102.04M, while operating income came in at 100.25M.

As of June 30, 2026, Kiniksa Pharmaceuticals International, plc holds 525.93M in cash and equivalents against 8.90M in total debt, resulting in a net debt position of -175.68M. Total book value stands at 654.15M, with working capital of 497.39M providing operational flexibility.

Kiniksa Pharmaceuticals International, plc produced 184.97M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -2.13M in capital expenditures, free cash flow totaled 182.84M - equivalent to 2.40 per share.

Over the twelve months ended June 30, 2026, Kiniksa Pharmaceuticals International, plc posted a gross margin of 54.50, reflecting its pricing power and cost economics. The operating margin of 11.92 and net profit margin of 9.59 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 3.49, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield is negative at -0.76, meaning Kiniksa Pharmaceuticals International, plc raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Kiniksa Pharmaceuticals International, plc has an Altman Z-Score of 13.71, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.